GOLDENWELL BIOTECH, INC. (GWLL) — SEC Financial Statements & Analysis

GOLDENWELL BIOTECH, INC. (GWLL) is a food and kindred products company, incorporated in NV. GOLDENWELL BIOTECH, INC. trades on OTC as: GWLL. GOLDENWELL BIOTECH, INC. (GWLL)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, GOLDENWELL BIOTECH, INC. carries a market cap of $51.48M, a P/E ratio of -277.69x, a P/B ratio of -129.28x, a P/S ratio of 935999.97x, an enterprise value of $51.47M, and an EV/EBITDA multiple of -448.33x. On profitability, it posts a gross margin of 28.46%, an operating margin of -208729.09%, a net margin of -337065.45%, a Return on Equity (ROE) of 72.10%, and a Return on Invested Capital (ROIC) of -144.47%. Per share, it reports EPS of $-0.00, diluted EPS of $-0.00, free cash flow per share of $-0.00, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -60.43% year-over-year, net income growth of 1110.72% year-over-year, and EPS growth of 1110.72% year-over-year. On the balance sheet, it maintains a debt-to-equity ratio of -1.07x, an interest coverage ratio of -18.22x, free cash flow of $-110.36K (TTM), and net debt of $-11.14K. Figures sourced from SEC EDGAR.

Market Cap

$51.48M

P/E TTM

-277.69x

EPS TTM

$-0.00

P/B TTM

-129.28x

ROE TTM

72.10%

Debt To Equity

-1.07x

Free Cash Flow TTM

$-110.36K

Net Revenue TTM Growth 1Y

-60.43%

Data as of 2026-06-30 · Source: SEC EDGAR